Back to search

Article

Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastoma

2024-12-21

Abstract excerpt

The vasodilator hydralazine (HYZ) has been used clinically for ∼ 70 years and remains on the World Health Organization’s List of Essential Medicines as a therapy for preeclampsia. Despite its longstanding use and the concomitant progress toward a general understanding of vasodilation, the target and mechanism of HYZ have remained unknown. We show that HYZ selectively targets 2-aminoethanethiol dioxygenase (ADO) by...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7b89d58a-a1d4-5dea-abf1-62bdd8ad4f38
DOI
10.1101/2024.12.19.629450
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastomaDOI 10.1101/2024.12.19.629450
Select a neighboring publication to make it the new centre.